Longboard Pharmaceuticals, Inc. (LBPH)
USD 59.98
(N/A%)
USD 59.98
(N/A%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -50.86 Million | -38.06 Million | -24.7 Million | -3.44 Million |
| Net Income | -54.42 Million | -43.94 Million | -27.79 Million | -14.4 Million |
| Depreciation & Amortization | 5000.00 | 5000.00 | 1000.00 | - |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 3.25 Million | 2.65 Million | 1.96 Million | 8.5 Million |
| Change in working capital | 1.26 Million | 3.11 Million | 967 Thousand | 2.45 Million |
| Other non-cash items | -972 Thousand | 101 Thousand | 157 Thousand | 7.29 Million |
| Investing Cash Flow | 24.23 Million | -17.06 Million | -40.71 Million | - |
| Investments in PPE | - | - | -16 Thousand | - |
| Acquisitions | - | - | - | - |
| Investment purchases | -71.71 Million | -57.61 Million | -40.7 Million | - |
| Sales/Maturities of investments | 95.95 Million | 40.55 Million | - | - |
| Other Investing Activities | 24.23 Thousand | -17.06 Thousand | -40.7 Thousand | - |
| Financing Cash Flow | 30.19 Million | -444 Thousand | 76.45 Million | 58.75 Million |
| Debt repayment | - | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | -1000.00 | -205 Thousand |
| Common Stock Issuance | 30.19 Million | - | 76.45 Million | 55.55 Million |
| Other Financing Activities | 30.19 Million | -444 Thousand | 76.45 Million | 3.4 Million |
| Accounts receivables | - | - | - | - |
| Accounts payables | -308 Thousand | 282 Thousand | -185 Thousand | 1.21 Million |
| Inventory | - | - | - | - |
| Other working capital | 1.57 Million | 2.83 Million | 1.15 Million | 1.23 Million |
| Cash at beginning of period | 10.77 Million | 66.34 Million | 55.31 Million | - |
| Cash at end of period | 14.33 Million | 10.77 Million | 66.34 Million | 55.31 Million |
| Capital Expenditure | - | - | -16 Thousand | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | 3.55 Million | -55.57 Million | 11.03 Million | 55.31 Million |
| Free Cash Flow | -50.86 Million | -38.06 Million | -24.72 Million | -3.44 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -21.78 Million | -14.98 Million | -54.42 Million | -15.03 Million | -12.93 Million | -14.99 Million |
| Depreciation & Amortization | 2000.00 | 1000.00 | 5000.00 | 1000.00 | 1000.00 | 2000.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.8 Million | 1.74 Million | 3.25 Million | 860 Thousand | 856 Thousand | 841 Thousand |
| Change in working capital | 2.89 Million | -92 Thousand | 1.26 Million | 3.54 Million | -1 Million | 1.07 Million |
| Other non-cash items | -1.66 Million | -141 Thousand | -972 Thousand | -397 Thousand | -203 Thousand | -371 Thousand |
| Investing Cash Flow | -20.68 Million | -230.91 Million | 24.23 Million | -1.56 Million | 11.74 Million | 7.96 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -98.88 Million | -255.11 Million | -71.71 Million | -18.66 Million | -18.65 Million | -13.83 Million |
| Sales/Maturities of investments | 78.2 Million | 24.2 Million | 95.95 Million | 17.1 Million | 30.4 Million | 21.8 Million |
| Other Investing Activities | -20.68 Million | -230.91 Thousand | 24.23 Thousand | -1561.00 | 11.74 Thousand | 7962.00 |
| Financing Cash Flow | 21 Thousand | 286.4 Million | 30.19 Million | 3.01 Million | 5.94 Million | -125 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 21 Thousand | 286.4 Million | 30.19 Million | 3.01 Million | 5.99 Million | -173 Thousand |
| Other Financing Activities | -4000.00 | -14.99 Million | 30.19 Million | 3.01 Million | 5.94 Million | -125 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.43 Million | 43 Thousand | -308 Thousand | 638 Thousand | -1.57 Million | 1.65 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.46 Million | -135 Thousand | 1.57 Million | 2.9 Million | 567 Thousand | -584 Thousand |
| Cash at beginning of period | 54.39 Million | 14.33 Million | 10.77 Million | 23.91 Million | 19.5 Million | 25.12 Million |
| Cash at end of period | 14.59 Million | 54.39 Million | 14.33 Million | 14.33 Million | 23.91 Million | 19.5 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -39.79 Million | 40.06 Million | 3.55 Million | -9.57 Million | 4.4 Million | -5.61 Million |
| Free Cash Flow | -19.13 Million | -15.17 Million | -50.86 Million | -11.02 Million | -13.28 Million | -13.45 Million |
6095
000540
PXPP
NODC
SRX
SBRANDS